Featured Research

from universities, journals, and other organizations

Duration of breastfeeding during infancy does not reduce a child's risk of being overweight, obese, study finds

Date:
March 12, 2013
Source:
The JAMA Network Journals
Summary:
In research that included nearly 14,000 healthy infants in Belarus, an intervention that succeeded in improving the duration and exclusivity of breastfeeding during infancy did not result in a lower risk of overweight or obesity among the children at age 11.5 years, according to a new study.

In research that included nearly 14,000 healthy infants in Belarus, an intervention that succeeded in improving the duration and exclusivity of breastfeeding during infancy did not result in a lower risk of overweight or obesity among the children at age 11.5 years, according to a study appearing in the March 13 issue of JAMA.

Observational studies suggest that greater duration and exclusivity of having been breastfed reduces child obesity risk. "However, breastfeeding and growth are socially patterned in many settings," and observed associations between these variables are at least partly explained by confounding factors, according to background information in the article.

Richard M. Martin, Ph.D., of the University of Bristol, England, and colleagues investigated the effects of an intervention to promote increased duration and exclusivity of breastfeeding on child adiposity (body fat) and circulating insulin-like growth factor 1 (IGF-1), which regulates growth. The randomized controlled trial was conducted in 31 Belarusian maternity hospitals and their affiliated clinics. Participants were randomized into 1 of 2 groups: breastfeeding promotion intervention or usual practices. Participants were 17,046 breastfeeding mother-infant pairs enrolled in 1996 and 1997, of whom 13,879 (81.4 percent) were followed up between January 2008 and December 2010 at a median (midpoint) age of 11.5 years. The breastfeeding promotion intervention was modeled on the WHO/UNICEF Baby-Friendly Hospital Initiative (World Health Organization/United Nations Children's Fund). The main outcome measures were body mass index (BMI), fat and fat-free mass indices (FMI and FFMI), percent body fat, waist circumference, triceps and subscapular skinfold thicknesses, overweight and obesity, and whole-blood IGF-1.

As previously reported, the researchers found that infants in the intervention group had substantially increased breastfeeding duration and exclusivity vs. the control group: at 3 months, exclusively (43.3 percent vs. 6.4 percent) and predominantly (51.9 vs. 28.3 percent) breastfed; at 6 months, both exclusive (7.9 percent vs. 0.6 percent) and predominant breastfeeding (10.6 percent vs. 1.6) were lower, but more common in the intervention group; and at 12 months, 19.7 percent (intervention) vs. 11.4 percent (control), were still breastfeeding to any degree.

At followup, when children were a median 11.5 years age, there were no significant differences between the experimental vs. control groups for the main outcomes, with the cluster-adjusted mean [average] differences of 0.19 (95 percent CI, -0.09 to 0.46) for BMI; 0.12 for FMI; 0.04 for FFMI; 0.47 percent for percent body fat; 0.30 cm for waist circumference; -0.07 mm for triceps and -0.02 mm for subscapular skinfold thicknesses; and -0.02 standard deviations for IGF-1.

The cluster-adjusted odds ratio for overweight/obesity (BMI ≥85th vs. <85th percentile) was 1.18 (95 percent CI, 1.01 to 1.39) and for obesity (BMI ≥95th vs. <85th percentile) was 1.17 (95 percent CI, 0.97 to 1.41).

"Among healthy term infants in Belarus, an intervention to improve the duration and exclusivity of infant breastfeeding did not prevent overweight or obesity, nor did it affect IGF-1 levels among these children when they were aged 11.5 years. Nevertheless, breastfeeding has many health advantages for the offspring, including beneficial effects demonstrated by our PROBIT trial on gastrointestinal infections and atopic eczema in infancy and improved cognitive development at age 6.5 years. Although breastfeeding is unlikely to stem the current obesity epidemic, its other advantages are amply sufficient to justify continued public health efforts to promote, protect, and support it," the researchers conclude.


Story Source:

The above story is based on materials provided by The JAMA Network Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Martin RM, Patel R, Kramer MS, et al. Effects of Promoting Longer-term and Exclusive Breastfeeding on Adiposity and Insulin-like Growth Factor-I at Age 11.5 Years: A Randomized Trial. JAMA, 2013; 309 (10): 1005-1013 DOI: 10.1001/jama.2013.167

Cite This Page:

The JAMA Network Journals. "Duration of breastfeeding during infancy does not reduce a child's risk of being overweight, obese, study finds." ScienceDaily. ScienceDaily, 12 March 2013. <www.sciencedaily.com/releases/2013/03/130312161151.htm>.
The JAMA Network Journals. (2013, March 12). Duration of breastfeeding during infancy does not reduce a child's risk of being overweight, obese, study finds. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/03/130312161151.htm
The JAMA Network Journals. "Duration of breastfeeding during infancy does not reduce a child's risk of being overweight, obese, study finds." ScienceDaily. www.sciencedaily.com/releases/2013/03/130312161151.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins